TG Therapeutics, Inc. (TGTX)
NASDAQ • Healthcare
Last close at November 18, 2026 at 21:00 UTC
Metrics Over Time
Where the Money Goes
Q3 2026In plain terms: out of every $100 in revenue, TG Therapeutics, Inc. keeps $21 as net profit.
Fundamentals & Financials
TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.
Income Statement
Balance Sheet
Financial Highlights
Dividends History
Split History
Earnings
% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS
TG Therapeutics’ third fiscal quarter of 2026 mixed a revenue beat with an EPS miss, as results reported November 9, 2026 showed revenue of $259.9 million topped the $245.5 million estimate (+5.9%) while EPS of $0.35 trailed the $0.37 estimate (-5%). Revenue rose ~61% year over year to about $259.9 million (up from about $161.7 million a year ago), reflecting a quarter driven by its therapy portfolio across oncology and immunology. Profitability remained elevated on a margin basis, with gross margin near 84% and operating margin around 33%, alongside gross profit of roughly $217.9 million and operating income of about $85.9 million. Below the operating line, net income fell ~86% year over year to about $55.5 million (down from roughly $390.9 million a year ago), and EPS declined ~86% from $2.43 a year ago to $0.35. The company generated operating cash flow of roughly $45.2 million during the quarter. For the next period, consensus calls for EPS of $0.45 on revenue of $269.5 million.
About TG Therapeutics, Inc.
TG Therapeutics, Inc. is a commercial-stage biotechnology company listed on the NASDAQ as TGTX that develops and sells therapies for B-cell related cancers and autoimmune disorders. FY2025 revenue was $616.3 million. Its business centers on monoclonal antibodies, targeted oral inhibitors, and earlier licensed programs in immunology and oncology.
Today's Snapshot
The day ended with TGTX 5.4% higher at 66.12, outperforming a weaker sector. TGTX closed within 2.8% of its 52-week high of 68.03. Analyst Julien Nono-Womdim named TG Therapeutics a top pick.
Trading Volume
Below 10d avg (2.5M)
1.8M
vs S&P 500 Today
Strong Outperformance
+5.70%
Updated: November 18, 2026 at 21:14 UTC
Technical Indicators
All signalsHide signals
- EMA (5 indicators)$46.55 - $63.18Buy
- RSI (14)66.21Neutral
- Stochastic %K (14, 3, 3)68.95Neutral
- MACD Level (12, 26)2.44Buy
Peers & Related Assets
Get premium market insights delivered directly to your inbox.